Artwork

Content provided by Dr. Kumar from LifeWellMD.com. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr. Kumar from LifeWellMD.com or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Shots of Hope: Ketamine Under the Skin, Not In Your Veins

12:24
 
Share
 

Manage episode 495212275 series 3606011
Content provided by Dr. Kumar from LifeWellMD.com. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr. Kumar from LifeWellMD.com or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Send us a text

Depression can feel like an endless battle, especially when treatments fail one after another. For those with treatment-resistant depression (TRD), that struggle becomes even more profound – affecting approximately one-third of people with major depressive disorder and creating a desperate need for new approaches.
The groundbreaking K-Day study brings fresh hope through an innovative approach: subcutaneous ketamine injections. While ketamine's potential for depression treatment isn't new, this research tackles a crucial practical challenge – finding an administration method that balances effectiveness with accessibility. Unlike complex IV setups or sometimes inconsistent nasal sprays, these under-the-skin injections represent a middle path that could dramatically expand treatment access.
What makes this study particularly compelling is how researchers adapted when initial results disappointed. By shifting from a fixed dose to a flexible, personalized approach that accounted for ketamine's lower absorption through subcutaneous administration, they achieved remarkable outcomes. The flexible-dosing group saw a 19.6% remission rate compared to just 2% in controls – particularly impressive in a population where nearly a quarter had even failed electroconvulsive therapy. The safety profile proved reassuring too, with expected short-term effects like dissociation and blood pressure changes consistently resolving within two hours, and no evidence of cognitive impairment.
While the benefits diminished somewhat after treatment stopped, suggesting ongoing treatment might be necessary for lasting relief, the research opens exciting possibilities. For TRD patients who've exhausted conventional options, subcutaneous ketamine could provide a practical pathway to relief without requiring complex clinical setups. Have you or someone you know struggled with depression that just won't respond to standard treatments? This research suggests better options might be on the horizon. Follow us for more breakthrough mental health developments that could transform treatment for those who need it most.

Disclaimer:
The information provided in this podcast is for educational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional before making changes to your supplement regimen or health routine. Individual needs and reactions vary, so it’s important to make informed decisions with the guidance of your physician.
Connect with Us:
If you enjoyed today’s episode, be sure to subscribe, leave us a review, and share it with someone who might benefit. For more insights and updates, visit our website at Lifewellmd.com.
Stay Informed, Stay Healthy:
Remember, informed choices lead to better health. Until next time, be well and take care of yourself.

  continue reading

Chapters

1. Understanding Treatment-Resistant Depression (00:00:00)

2. The K-Day Study Design (00:01:48)

3. Flexible Dosing Makes Dramatic Difference (00:04:28)

4. Safety Profile and Side Effects (00:06:38)

5. Long-Term Benefits and Future Research (00:09:13)

6. Clinical Implications and Conclusion (00:11:21)

132 episodes

Artwork
iconShare
 
Manage episode 495212275 series 3606011
Content provided by Dr. Kumar from LifeWellMD.com. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr. Kumar from LifeWellMD.com or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Send us a text

Depression can feel like an endless battle, especially when treatments fail one after another. For those with treatment-resistant depression (TRD), that struggle becomes even more profound – affecting approximately one-third of people with major depressive disorder and creating a desperate need for new approaches.
The groundbreaking K-Day study brings fresh hope through an innovative approach: subcutaneous ketamine injections. While ketamine's potential for depression treatment isn't new, this research tackles a crucial practical challenge – finding an administration method that balances effectiveness with accessibility. Unlike complex IV setups or sometimes inconsistent nasal sprays, these under-the-skin injections represent a middle path that could dramatically expand treatment access.
What makes this study particularly compelling is how researchers adapted when initial results disappointed. By shifting from a fixed dose to a flexible, personalized approach that accounted for ketamine's lower absorption through subcutaneous administration, they achieved remarkable outcomes. The flexible-dosing group saw a 19.6% remission rate compared to just 2% in controls – particularly impressive in a population where nearly a quarter had even failed electroconvulsive therapy. The safety profile proved reassuring too, with expected short-term effects like dissociation and blood pressure changes consistently resolving within two hours, and no evidence of cognitive impairment.
While the benefits diminished somewhat after treatment stopped, suggesting ongoing treatment might be necessary for lasting relief, the research opens exciting possibilities. For TRD patients who've exhausted conventional options, subcutaneous ketamine could provide a practical pathway to relief without requiring complex clinical setups. Have you or someone you know struggled with depression that just won't respond to standard treatments? This research suggests better options might be on the horizon. Follow us for more breakthrough mental health developments that could transform treatment for those who need it most.

Disclaimer:
The information provided in this podcast is for educational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional before making changes to your supplement regimen or health routine. Individual needs and reactions vary, so it’s important to make informed decisions with the guidance of your physician.
Connect with Us:
If you enjoyed today’s episode, be sure to subscribe, leave us a review, and share it with someone who might benefit. For more insights and updates, visit our website at Lifewellmd.com.
Stay Informed, Stay Healthy:
Remember, informed choices lead to better health. Until next time, be well and take care of yourself.

  continue reading

Chapters

1. Understanding Treatment-Resistant Depression (00:00:00)

2. The K-Day Study Design (00:01:48)

3. Flexible Dosing Makes Dramatic Difference (00:04:28)

4. Safety Profile and Side Effects (00:06:38)

5. Long-Term Benefits and Future Research (00:09:13)

6. Clinical Implications and Conclusion (00:11:21)

132 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play